Carregant...
The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report
Acquired mutations in anaplastic lymphoma kinase (ALK) gene have been implicated as the major resistance mechanism to ALK inhibitors; however, information on the treatment options after acquiring novel ALK secondary mutations is limited. Herein, we report the efficacy of lorlatinib upon the detectio...
Guardat en:
| Publicat a: | Cancer Biol Ther |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7834046/ https://ncbi.nlm.nih.gov/pubmed/33380260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1836947 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|